Intellia Therapeutics

We're a #GeneEditing company, developing novel, potentially curative therapeutics leveraging #CRISPR-based technologies. Guidelines:

[Intellia Therapeutics @intelliatx]

What does it really mean to live with #HereditaryAngioedema? HAE is a rare and complex condition that can impact nearly every aspect of daily life.

Intellia's latest educational resource, HAE Reframed, seeks to deepen the understanding of the full burden of the disease. Learn more: https://t.co/vcccERe5wK.

This website is intended for U.S. audiences only.

[Intellia Therapeutics @intelliatx]

#HAE News: Intellia is proud to share additional positive Phase 3 HAELO results at #EAACICongress2026 and a simultaneous publication of the data in @NEJM, marking our sixth publication in this renowned journal 🧬. Full details: https://t.co/5zAkiylDCc

[Intellia Therapeutics @intelliatx]

Our team's bags are packed, and we're headed to the Netherlands for the @PNSociety1 Annual Meeting this weekend! You'll find us at our medical tabletop discussing all things Intellia. HCPs: Stop by and say hello!

[Intellia Therapeutics @intelliatx]

Intellia recently welcomed several new members to its Field Medical and Commercial teams!

The week was packed with on-site workshops, followed by an exclusive behind-the-scenes lab tour to see the incredible science driving our mission forward. And of course, no week of training would be complete without a little fun on the pickleball court and mini golf!

We are so excited to have this talented group on board and look forward to all that we will accomplish together. #OneIntellia

[Intellia Therapeutics @intelliatx]

Intellia is looking forward to giving a late-breaking oral presentation highlighting additional data from HAELO, our Phase 3 clinical trial in #HereditaryAngioedema, and to sharing new research on patients’ continued unmet needs at the upcoming @EAACI_HQ Congress. More details here: https://t.co/2DvsBKQuhd

[Intellia Therapeutics @intelliatx]

This weekend, Intellia will have a medical tabletop at the Eastern Allergy Conference in Palm Beach, FL. HCPs: Swing by to meet the team and review our latest educational material.

https://t.co/vcR5kCeW7q

[Intellia Therapeutics @intelliatx]

It's #HAEDay: We stand in unity with the #hereditaryangioedema community.

This year was extra special, in part because of our incredible guest speaker, Kim, who spent the day with us to share her HAE story and lived experiences. We are immensely grateful for her time and invaluable insights. Here are some of our favorite moments. #active4HAE

https://t.co/ue046HM2ob

[Intellia Therapeutics @intelliatx]

We're excited to launch our newest educational website, designed specifically for U.S. healthcare professionals, shedding light on the challenges for those living with #hereditaryangioedema.

Hereditary Angioedema (HAE) is a rare and often misunderstood condition, and its full impact goes beyond physical attacks. HCPs, visit https://t.co/nedrdcTr5W to learn more about the burden of #HAE.

This website is intended for U.S. healthcare professionals only.

[Intellia Therapeutics @intelliatx]

Intellia ($NTLA) today reported its first quarter 2026 financial results and recent company progress. Full details here: https://t.co/OYjJL3BYPu

[Intellia Therapeutics @intelliatx]

This weekend, you'll find the Intellia team at the European Society of Cardiology (@escardio) Heart Failure Congress in Barcelona, Spain. Looking forward to our presentation on May 11. HCPs: Be sure to tune in!

https://t.co/vcR5kCeW7q

[Intellia Therapeutics @intelliatx]

This week, members of the Intellia team will be at our booth at the @MethodistHosp 4th Annual Bradley Z. Naifeh #Amyloidosis Conference in Houston, TX. We look forward to meeting you and the insightful conversations ahead! #ATTR

https://t.co/vcR5kCeW7q

[Intellia Therapeutics @intelliatx]

Great way to wrap up a historic week! We’re honored to light up the iconic Nasdaq Tower in Times Square celebrating Intellia's recent #CRISPR milestone. A big thanks to @Nasdaq for recognizing our recent HAELO topline data, a first ever for in vivo #geneediting.

[Intellia Therapeutics @intelliatx]

We have initiated a rolling Biologics License Application (BLA) submission to the @FDA to seek approval for our lead candidate as a potential one-time treatment for hereditary angioedema (#HAE). Read the press release here: https://t.co/js8lE5nlb8

[Intellia Therapeutics @intelliatx]

We are thrilled to share the first-ever Phase 3 results for an in vivo #CRISPR-based therapy. This morning, we shared positive topline results from HAELO, our Phase 3 clinical trial in #hereditaryangioedema. Join our webcast today at 8am ET. Full details: https://t.co/a9erIcd4Ol

[Intellia Therapeutics @intelliatx]

It's #DNADay!🧬

Today, we celebrate the completion of the Human Genome Project and the breakthrough discovery of the DNA double helix.

Here's to recognizing all the scientists and innovators who continue to unlock the power of DNA to advance the future of medicine. 🔬

https://t.co/ue046HM2ob

[Intellia Therapeutics @intelliatx]

#HAE News: Intellia will host a conference call on Monday, April 27 at 8am ET to discuss results from its Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z, 50 mg) for #hereditaryangioedema.
https://t.co/tOVpzVcb69

[Intellia Therapeutics @intelliatx]

Happy #AdministrativeProfessionalsDay! 🌟

Behind every seamless event and every booked flight is the unstoppable force of our incredible team. Your hard work and attention to detail never go unnoticed. Thank you for all you do to support us. We appreciate you today and every day! #OneIntellia

[Intellia Therapeutics @intelliatx]

This week, we will be at the Consortium of Independent Immunology Clinics (#CIIC) Spring Meeting in Arlington, TX.

HCPs: Swing by our booth to say hello and learn more about Intellia. We’re excited to engage in meaningful discussions in the days to come.

#CIIC2026 #AllergyImmunology

https://t.co/ue046HM2ob

[Intellia Therapeutics @intelliatx]

What is in vivo #geneediting?

In vivo means "within the living." This type of gene editing therapy is administered directly into the body, typically intravenously, or into the veins, to edit a particular gene with the goal of treating a disease.

Learn more about #CRISPR: https://t.co/q6Lnx1t8yf

[Intellia Therapeutics @intelliatx]

Our medical affairs team will be at the @ACCinTouch Annual Scientific Session this weekend in New Orleans, LA.

HCPs: Be sure to stop by our booth to meet our team and learn more about Intellia, #CRISPR and #ATTR.